2. Search Result
Search Result
Results for "

intestinal inflammatory

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

2

Screening Libraries

2

Peptides

13

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2155
    Acotiamide monohydrochloride trihydrate

    		Cholinesterase (ChE) Metabolic Disease Inflammation/Immunology
    Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide monohydrochloride trihydrate
  • HY-N0847
    Micheliolide
    4 Publications Verification

    		 NF-κB PI3K Akt TGF-beta/Smad Inflammation/Immunology Cancer
    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .
    Micheliolide
  • HY-P2221B
    Glepaglutide acetate

    ZP1848 acetate

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide acetate
  • HY-121467A
    Acotiamide hydrochloride

    Z-338; YM443

    		 Cholinesterase (ChE) Others Metabolic Disease Inflammation/Immunology
    Acotiamide hydrochloride is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide hydrochloride can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide hydrochloride has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide hydrochloride
  • HY-121467
    Acotiamide

    Z-338 free base; YM443 free base

    		 Cholinesterase (ChE) Metabolic Disease Inflammation/Immunology
    Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide
  • HY-B2155R
    Acotiamide monohydrochloride trihydrate (Standard)

    		Cholinesterase (ChE) Metabolic Disease Inflammation/Immunology
    Acotiamide (monohydrochloride trihydrate) (Standard) is the analytical standard of Acotiamide (monohydrochloride trihydrate). This product is intended for research and analytical applications. Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC50 of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide monohydrochloride trihydrate (Standard)
  • HY-167719
    Dersalazine

    UR-12746 free base

    		 Others Inflammation/Immunology
    Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
    Dersalazine
  • HY-123505
    Dersalazine sodium

    UR-12746 sodium

    		 Platelet-activating Factor Receptor (PAFR) Interleukin Related Inflammation/Immunology
    Dersalazine (sodium) is a platelet-activating factor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression .
    Dersalazine sodium
  • HY-P2221
    Glepaglutide

    ZP1848

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide
  • HY-163466
    FXR agonist 7

    		FXR Inflammation/Immunology
    FXR agonist 7 (compound 33) is a potent agonist of FXR, with EC50 of 0.1 nM. FXR agonist 7 shows high intestinal distribution, good anti-inflammatory activity .
    FXR agonist 7
  • HY-I0746
    3-Aminobenzoic acid

    m-Aminobenzoic acid; 3ABA

    		 Endogenous Metabolite Neurological Disease Inflammation/Immunology
    3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
    3-Aminobenzoic acid
  • HY-W097994
    DHMB

    2,3-Dihydroxy-4-methoxybenzaldehyde

    		 Fungal Infection Inflammation/Immunology
    DHMB (2,3-Dihydroxy-4-methoxybenzaldehyde) is a small organic molecule with anti-fungal and anti-inflammatory activity. DHMB has protective effect on intestinal epithelial cells .
    DHMB
  • HY-N7541
    Antrodin A

    		Others Inflammation/Immunology
    Antrodin A is one of the main active ingredients in the solid-state fermented A. camphorate mycelium. Antrodin A protects the liver from alcohol damage by improving the antioxidant and anti-inflammatory capacity of the liver and maintaining the stability of the intestinal flora .
    Antrodin A
  • HY-107616
    H2L5186303
    1 Publications Verification

    		 LPL Receptor Apoptosis Others
    H2L5186303 is an effective and selective LPA2 receptor antagonist, with an IC50 of 9 nM, and it has anti-inflammatory effects. H2L5186303 can inhibit intestinal cell proliferation and promote apoptosis .
    H2L5186303
  • HY-I0746R
    3-Aminobenzoic acid (Standard)

    		Endogenous Metabolite Neurological Disease Inflammation/Immunology
    3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
    3-Aminobenzoic acid (Standard)
  • HY-156550
    ROCK-IN-8

    		ROCK Inflammation/Immunology
    ROCK-IN-8 (Example 4) is a ROCK inhibitor, with an IC50 value less than 100 nM. ROCK-IN-8 has anti-inflammatory activity. ROCK-IN-8 can be used for research of respiratory and gastro-intestinal diseases .
    ROCK-IN-8
  • HY-147105
    LRH-1 modulator-1

    		Orphan Receptor Inflammation/Immunology
    LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 shows anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces anti-inflammatory cytokine IL-10, and reduces inflammatory cytokine IL-1b and TNFa .
    LRH-1 modulator-1
  • HY-N10587
    Catechin 7-O-β-D-glucopyranoside

    		Others Inflammation/Immunology
    Catechin 7-O-beta-D-glucopyranoside is an orally active natural product found in Ulmus davidiana and Paeonia obovata. Catechin 7-O-β-D-glucopyranoside shows antioxidant and anti-inflammatory activities, and attenuates mitochondrial dysfunction. Catechin 7-O-beta-D-glucopyranoside can be used in intestinal inflammatory disease research .
    Catechin 7-O-β-D-glucopyranoside
  • HY-125130
    Hesperetin 7-O-glucoside

    Hes-7-G

    		 HMG-CoA Reductase (HMGCR) Bacterial Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    Hesperetin 7-O-glucoside is a typical flavonoid monoglucoside, which is an anti-inflammatory agent and an antihypertensive with orally active. Hesperetin 7-O-glucoside is a commonly used food adjuvant. Hesperetin 7-O-glucoside inhibits human intestinal maltase and human HMG-CoA reductase with Ki of 1.8 mM and 9.8 μM, respectively. Hesperetin 7-O-glucoside has antibacterial activity and can regulate intestinal flora and metabolic homeostasis in mice .
    Hesperetin 7-O-glucoside
  • HY-138962
    κ-Carrageenan

    K-Carrageenan Karra Type

    		 Apoptosis Inflammation/Immunology Cancer
    κ-Carrageenan is a natural polymer which predominantly available in red seaweeds. κ-Carrageenan is an effective agent carrier to deliver curcumin in cancer cells and to induce apoptosis. κ-carrageenan serves as a potential inflammatory agent that magnifies existing intestinal inflammation .
    κ-Carrageenan
  • HY-162797
    PDE4-IN-18

    		Phosphodiesterase (PDE) TNF Receptor Interleukin Related Inflammation/Immunology
    PDE4-IN-18 (compound 1l) is a PDE4 inhibitor (IC50=1.55 μM) with anti-inflammatory activity. PDE4-IN-18 exerts anti-inflammatory effects by reducing excessive immune cell infiltration and intestinal membrane formation, as well as reducing the mRNA expression of pro-inflammatory cytokines (such as TNF-α and IL-6) in synovial tissue. PDE4-IN-18 can be used in the study of rheumatoid arthritis and psoriasis .
    PDE4-IN-18
  • HY-N6996
    Methyl Eugenol

    		Autophagy PI3K mTOR Akt Inflammation/Immunology Cancer
    Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury .
    Methyl Eugenol
  • HY-N6612B
    Glucuronic acid sodium

    		Others Inflammation/Immunology
    Glucuronic acid sodium is a polysaccharide that exhibits anti-inflammatory activity, supporting the healing of ulcerative colitis. Glucuronic acid sodium also enhances the intestinal barrier by upregulating tight junction proteins like ZO-1 and Occludin. Furthermore, Glucuronic acid sodium plays a role in modulating gut microbiota by increasing beneficial bacterial populations while suppressing harmful ones.
    Glucuronic acid sodium
  • HY-147105A
    (+)-LRH-1 modulator-1

    		Interleukin Related Inflammation/Immunology
    (+)-LRH-1 modulator-1 is a stereoisomer of LRH-1 modulator-1. LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 has anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and reduces the inflammatory cytokines IL-1b and TNFa .
    (+)-LRH-1 modulator-1
  • HY-16569
    Colchicine
    Maximum Cited Publications
    32 Publications Verification

    		 Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis Cancer
    Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine
  • HY-113212
    Ursocholic acid

    		Endogenous Metabolite Apoptosis Metabolic Disease Inflammation/Immunology
    Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .
    Ursocholic acid
  • HY-103370
    Talniflumate

    BA 7602-06

    		 Chloride Channel Inflammation/Immunology
    Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase . Talniflumate is an orally active Ca 2+-activated Cl - channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome .
    Talniflumate
  • HY-105017
    Evodenoson

    ATL 313; DE 112

    		 Adenosine Receptor Infection Inflammation/Immunology
    Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .
    Evodenoson
  • HY-N6996R
    Methyl Eugenol (Standard)

    		Autophagy PI3K mTOR Akt Inflammation/Immunology Cancer
    Methyl Eugenol (Standard) is the analytical standard of Methyl Eugenol. This product is intended for research and analytical applications. Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury .
    Methyl Eugenol (Standard)
  • HY-16569R
    Colchicine (Standard)

    		Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis Cancer
    Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine (Standard)
  • HY-W007376
    Indole-3-carboxaldehyde

    3-Formylindole

    		 Endogenous Metabolite Others
    Indole-3-carboxaldehyde (3-Formylindole), a banlangen extract, is the product of the oxidative degradation of indole-3-acetic acid (IAA) by crude enzyme preparations from etiolated pea seedlings. Indole-3-carboxaldehyde is a biochemical used to prepare analogs of the indole phytoalexin cyclobrassinin. Indole-3-carboxaldehyde also enhances the epithelial barrier and anti-inflammatory activity in the intestinal tract .
    Indole-3-carboxaldehyde
  • HY-N9448
    Lacto-N-tetraose

    		Bacterial Infection Inflammation/Immunology
    Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula .
    Lacto-N-tetraose
  • HY-15048
    GPI 15427

    		PARP Inflammation/Immunology
    GPI 15427 is a potent inhibitor of the enzyme poly (ADP-ribose) polymerase-1 (PARP-1), which plays a harmful role during inflammation. In a rat model of gut injury and inflammation, including splanchnic artery occlusion (SAO) shock and dinitrobenzene sulfonic acid (DNBS)-induced colitis, GPI 15427 demonstrated strong anti-inflammatory effects. It reduced inflammatory cell infiltration, histological injury, and delayed clinical signs of inflammation. GPI 15427 also diminished the accumulation of poly (ADP-ribose) in the ileum and colon of treated rats. These results suggest GPI 15427 could be useful for treating intestinal ischemia and inflammation .
    GPI 15427
  • HY-B0595
    Ramosetron Hydrochloride

    YM060

    		 5-HT Receptor Neurological Disease Inflammation/Immunology Cancer
    Ramosetron (YM060 free base) Hydrochloride is an orally active 5-HT3 antagonist that improves dysphoria, interference with activity and food avoidance. Ramosetron Hydrochloride is promising for research of irritable bowel syndrome with diarrhea .
    Ramosetron Hydrochloride
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    		 Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-17623S
    Tegoprazan-d6

    CJ-12420-d6; RQ-00000004-d6

    		 Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-N0469R
    L-Lysine (Standard)

    		Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)
  • HY-15026
    ATB 429

    		Endogenous Metabolite Inflammation/Immunology
    ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
    ATB 429

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: